Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 15/20 | 0.60 |
| ▸ | EGLN2 | Q96KS0 | 15/20 | 0.60 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.57 |
| ▸ | THRA | P10827 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | ASPH | Q12797 | 1/20 | 0.57 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.57 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Roxadustat SCHEMBL3916306 | 0.86 | EGLN1 (0.81) | EGLN1EGLN2BBOX1THRATHRB | |
| SCHEMBL3916308 | 0.86 | EGLN2 (0.62) | EGLN1EGLN2THRATHRB | |
| SCHEMBL523000 | 0.81 | EGLN2 (0.70) | EGLN1EGLN2 | |
| SCHEMBL523001 | 0.81 | EGLN2 (0.70) | EGLN1EGLN2 | |
| SCHEMBL28536064 | 0.81 | EGLN1 (0.70) | EGLN1EGLN2BBOX1THRATHRB | |
| SCHEMBL5030253 | 0.81 | EGLN1 (0.61) | EGLN1EGLN2BBOX1THRATHRB | |
| SCHEMBL522778 | 0.80 | EGLN2 (0.68) | EGLN1EGLN2 | |
| SCHEMBL522777 | 0.80 | EGLN2 (0.68) | EGLN1EGLN2 | |
| SCHEMBL22722546 | 0.80 | EGLN1 (0.69) | EGLN1EGLN2BBOX1THRATHRB | |
| SCHEMBL30402374 | 0.80 | EGLN2 (0.68) | EGLN1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009002533-A1 | INFLAMMATORY BOWEL DISEASE THERAPIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2008-12-31 | — | — | WO | disclosed |